20-OCT-2026 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 1 Y 1 Tissue for MammaPrint testing 960 1249 531 249 125 46 9 11/27/2023 398 130
            1249 531 249 125 46 9      
 
    2 Y 2 SOC Chemotherapy   214 90 34 14 5 1 11/27/2023    
        3 SOC Chemotherapy + Durvalumab   212 89 34 17 7 3      
            426 179 68 31 12 4      
 
  S2212-Breast, TNBC, Neoadj Chemo + Pembro 1 Y 1 Carbo + Paclitaxel + Pembro -> AC + Pembro 2400 877 408 211 105 34 6 09/15/2023 451 163
        2 Carbo + Docetaxel + Pembro   874 402 211 100 35 7      
            1751 810 422 205 69 13      
 
Yes A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib 1 E Total Registrations   55 0 0 0 0 0 03/11/2021 464 191
            55 0 0 0 0 0      
 
  A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab 1 E Total Registrations   69 27 17 8 3 0 08/24/2023 439 184
            69 27 17 8 3 0      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 T Total Registrations   1 0 0 0 0 0 09/22/2017    
            1 0 0 0 0 0      
 
  NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 1 T Total Registrations   7 0 0 0 0 0 06/22/2018    
            7 0 0 0 0 0      
 
No A012303-Breast, HER2+, Shortened Adj 1 E Total Registrations   5 5 3 0 0 0 03/06/2026 80 32
            5 5 3 0 0 0      
 
  NRGBR009-Breast, EarlyStg, Adjuvant Chemo 1 E Total Registrations   68 43 21 13 0 0 01/31/2024 521 197
            68 43 21 13 0 0      
 
    2 E Total Registrations   50 28 10 6 1 0 01/31/2024    
            50 28 10 6 1 0      
 

20-OCT-2026 6:10

BREAST Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2511 Brst, de novo StgIV oligo, locoreg tx vs SOC 1 Initial Registration 18-Aug-26 106 27
  2 Cohort Assignment/Randomization 18-Aug-26 106 27